Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
Sign Up to like & getrecommendations! Published in 2018 at "Investigational New Drugs"
DOI: 10.1007/s10637-018-0688-4
Abstract: SummaryPurpose To determine the maximum tolerated dose (MTD) of F14512, a topoisomerase II inhibitor designed to target cancer cells through the polyamine transport system, (three-hour daily infusion given for 3 consecutive days every 3 weeks) in… read more here.
Keywords: topoisomerase inhibitor; resistant ovarian; study; platinum refractory ... See more keywords
A novel topoisomerase 2a inhibitor, cryptotanshinone, suppresses the growth of PC3 cells without apparent cytotoxicity
Sign Up to like & getrecommendations! Published in 2017 at "Toxicology and Applied Pharmacology"
DOI: 10.1016/j.taap.2017.07.007
Abstract: ABSTRACT DNA topoisomerase 2, which is ubiquitously expressed in eukaryotic cells, is an essential nuclear enzyme that promotes cell survival by regulating DNA topology and chromatid separation. This enzyme has been validated as a target… read more here.
Keywords: topoisomerase inhibitor; novel topoisomerase; cryptotanshinone; topoisomerase ... See more keywords
Molecular docking, DFT and antimicrobial studies of Cu(II) complex as topoisomerase I inhibitor
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Biomolecular Structure and Dynamics"
DOI: 10.1080/07391102.2020.1743365
Abstract: Abstract Herein, we report the synthesis and single crystal X-ray structure of Cu(II)-picolinic acid complex, 1 as a potent topoisomerase I inhibitor. The complex 1 crystallized in the triclinic crystal system with space group P-1.… read more here.
Keywords: topoisomerase inhibitor; studies complex; docking dft; molecular docking ... See more keywords
PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-22-0217
Abstract: Alterations in the ATM gene are among the most common somatic and hereditary cancer mutations, and ATM-deficient tumors are hypersensitive to DNA damaging agents. A synthetic lethal combination of DNA damaging agents and DNA repair… read more here.
Keywords: atm deficient; deficient; deficient tumors; topoisomerase inhibitor ... See more keywords
High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers14010002
Abstract: Simple Summary Despite significant advancement in therapeutic strategies, breast cancers remain the most prevalent type of cancer in terms of incidence and mortality worldwide. Therefore, new alternative therapies have become an urgent clinical need. The… read more here.
Keywords: cancer; breast cancer; apoptosis; dual topoisomerase ... See more keywords
Recurrent Translocations in Topoisomerase Inhibitor-Related Leukemia Are Determined by the Features of DNA Breaks Rather Than by the Proximity of the Translocating Genes
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23179824
Abstract: Topoisomerase inhibitors are widely used in cancer chemotherapy. However, one of the potential long-term adverse effects of such therapy is acute leukemia. A key feature of such therapy-induced acute myeloid leukemia (t-AML) is recurrent chromosomal… read more here.
Keywords: translocations topoisomerase; recurrent translocations; proximity; leukemia ... See more keywords